SWOG clinical trial number
S0535

A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Abbreviated Title
Phase II ATRA, Arsenic and Mylotarg for Untreated High-Risk APL
Activated
11/15/2007
Participants
NCORP, Members, Medical Oncologists, Pathologists, CTSU, Affiliates

Research committees

Leukemia

Treatment

6-Mercaptopurine All trans retinoic acid Daunomycin Methotrexate Arsenic Trioxide Gemtuzumab Ozogamicin

Other Clinical Trials

CTSU/A042001
SWOG Clinical Trial Number

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
S1925
SWOG Clinical Trial Number

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
57% Accrual
Accrual
57%
Open
Phase
CTSU/AALL1821
SWOG Clinical Trial Number

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Research Committee(s)
Leukemia
Activated
12/04/2020
Open